JUAN IGNACIO
ARENAS MIRAVE
Forscher/in in der Zeit 1985-2014
Publikationen (105) Publikationen von JUAN IGNACIO ARENAS MIRAVE
2020
2017
-
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237
2015
-
Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España
Gastroenterologia y Hepatologia, Vol. 38, Núm. 4, pp. 263-273
-
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174
-
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities
European Journal of Gastroenterology and Hepatology, Vol. 27, Núm. 1, pp. 46-54
-
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis
Liver International, Vol. 35, Núm. 1, pp. 90-100
-
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program
Journal of Viral Hepatitis, Vol. 22, Núm. 5, pp. 469-480
2013
-
Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice
Annals of Hepatology, Vol. 12, Núm. 2, pp. 205-212
2012
-
Accurate fat fraction quantification by multiecho gradient-recalled-echo magnetic resonance at 1.5 T in rats with nonalcoholic fatty liver disease
European Journal of Radiology, Vol. 81, Núm. 6, pp. 1122-1127
-
Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening
New England Journal of Medicine, Vol. 366, Núm. 8, pp. 697-706
-
Effect of neoadjuvant chemotherapy in hepatic steatosis
Chemotherapy, Vol. 58, Núm. 2, pp. 89-94
-
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
Cancer Cell International, Vol. 12
2011
2010
-
Biochemical determination of lipid content in hepatic steatosis by the Soxtec method
World Journal of Gastroenterology, Vol. 16, Núm. 12, pp. 1495-1499
-
Colorectal cancer prognosis twenty years later
World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867
-
Inflammatory mediators of hepatic steatosis
Mediators of Inflammation, Vol. 2010
-
Niveles plasmóticos de la vitamina B12 y ácido fólicoenpacientes con hepatopatía crónica
Gastroenterologia y Hepatologia, Vol. 33, Núm. 4, pp. 280-287
-
Outcome of liver transplantation using donors older than 60 year of age
Clinical Transplantation, Vol. 24, Núm. 4, pp. 543-549
2009
-
Trends in Barrett's esophagus diagnosis in Southern Europe: Implications for surveillance
Diseases of the Esophagus, Vol. 22, Núm. 3, pp. 239-248
2008
-
Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis
World Journal of Gastroenterology, Vol. 14, Núm. 10, pp. 1521-1527